Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevalence and Severity of Acne Vulgaris in Adolescents Receiving Spironolactone
TCTR20250206004Completed
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of spironolactone in acne vulgaris (2 arms), sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoints: Prevalence of acne vulgaris in adolescents receiving spironolactone and Severity of acne vulgaris in adolescents receiving spironolactone. Started Jan 2024; status: completed.
02
Drugs
spironolactone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on TCTR20250206004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250206004.